SynthesisMedical sciences (Basel, Switzerland)2026
Radiologic-Pathologic Discordance After Image-Guided Breast Biopsy: A Systematic Review of Prevalence and Outcomes.
Synthesis in Medical sciences (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiologic-pathologic discordance remains an important concern owing to the absence of standardized guidelines. This systematic review aimed to summarize the prevalence of discordant benign outcomes, defined as suspicious imaging findings with benign biopsy histology insufficient to explain the imaging abnormality, and to quantify malignancy upgrades subsequent to additional tissue assessment.
methodsThis review was conducted in accordance with PRISMA 2020 guidelines and was prospectively registered. Eligible studies reported primary patient-level or aggregated data on radiologic-pathologic correlations post-image-guided breast biopsy and provided extractable data on discordant benign prevalence and/or subsequent malignancy upgrades.
resultsTwenty-three studies were included. Lesion-/biopsy-based cohorts focused on biopsied abnormalities for analysis. Twelve studies directly estimated discordant-benign prevalence, whereas 11 studies did not, as study designs were discrepant-only, lesion-defined, or excision-restricted. Unselected cohorts with a cohort-wide correlation reported 1.2-5.3% discordant benign prevalence for all biopsies. When restricted to excised lesions, the discordant benign ascertainment rate was 7.4%, representing an excision-ascertained subset rather than the cohort-wide prevalence. Using benign-biopsy denominators, the discordance rate was 1.5-19.2%. Malignancy upgrades among discordant benign lesions ranged from 0 to 100% in selected subsets; however, several clinically relevant cohorts reported representative rates of approximately 20-40%, with some high-risk cohorts exceeding 50%.
conclusionsDiscordant benign biopsy results are rare in unselected biopsy populations but carry a clinically meaningful upgrade risk, which warrants structured radiologic-pathologic correlation and prompt diagnostic resolution through repeat sampling or excision. Improvements in comparability and management algorithms require standardized definitions, uniform denominators aligned with all biopsied lesions, and prospective multicenter designs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.